Observational studyClinical oral investigations2026
Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study.
Observational study in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo characterize invasive dental procedures in romosozumab-treated osteoporosis patients and describe medication-related osteonecrosis of the jaw (MRONJ) according to exposure timing.
methodsThis retrospective study used electronic medical records and prescription/administration data from Yonsei University Dental Hospital between 2019 and 2024. Participants who received romosozumab, underwent tooth extraction and/or implant placement, and had at least 6 months of follow-up were included. Invasive dental procedures were categorized according to the timing of romosozumab administration relative to dental treatment (before, after, or both before and after treatment). MRONJ was identified according to American Association of Oral and Maxillofacial Surgeons criteria. Analyses were descriptive.
resultsA total of 201 participants underwent 303 invasive procedures (231 extractions, 72 implants). Extractions were most commonly performed for retained root (30.3%), caries (22.1%), periodontal disease (19.0%), and fractures (11.7%). Among the procedures, 77 (25.4%) were categorized as before dental treatment, 182 (60.1%) as after dental treatment, and 44 (14.5%) as before and after dental treatment relative to romosozumab administration. One case of MRONJ occurred in a participant with sequential exposure to denosumab, romosozumab, and subsequent intravenous zoledronic acid therapy, accompanied by local infection.
conclusionsA causal relationship with romosozumab monotherapy could not be determined because MRONJ occurred during cumulative and sequential antiresorptive exposure with local infection. Larger studies are needed to assess risks related to treatment sequence and cumulative exposure. CLINICAL RELEVANCE: Clinicians managing patients receiving romosozumab should consider cumulative antiresorptive exposure, local infection, and close coordination between physicians and dentists.
Indexed as
Identifiers
42437851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.